The FLT3-like Gene Expression Signature Predicts Response to Quizartinib in Wild-Type FLT3 Acute Myeloid Leukemia: An Analysis of the Pethema Quiwi TrialAdrián Mosquera Orgueira, Pau Montesinos, Víctor Noriega et al.|Blood|2023Cited by 15
S130: PRELIMINARY RESULTS OF QUIWI: A DOUBLE BLINDED, RANDOMIZED CLINICAL TRIAL COMPARING STANDARD CHEMOTHERAPY PLUS QUIZARTINIB VERSUS PLACEBO IN ADULT PATIENTS WITH NEWLY DIAGNOSED FLT3-ITD WILD-TYPE AMLPau Montesinos, Jorge Labrador, Rebeca Rodríguez‐Veiga et al.|HemaSphere|2023Cited by 14
Final Results of Quiwi: A Double Blinded, Randomized Pethema Trial Comparing Standard Chemotherapy Plus Quizartinib Versus Placebo in Adult Patients with Newly Diagnosed <i>FLT3</i>-ITD Negative AMLPau Montesinos, Jorge Labrador, Rebeca Rodríguez‐Veiga et al.|Blood|2024Cited by 5
Enhanced Validation of the <i>FLT3</i>-like Gene Expression Signature As a Predictive Biomarker for Quizartinib Response in <i>FLT3-ITD</i> Negative Acute Myeloid Leukemia: Expanded Cohort and Extended Follow-up from the Pethema Quiwi TrialAdrián Mosquera Orgueira, Pau Montesinos, Manuel Pérez‐Encinas et al.|Blood|2024Cited by 3
Exploring Potential Molecular Mechanisms of Drug Response in FLT3-ITD Negative AML Patients Treated with Quizartinib Vs Placebo Plus Standard Chemotherapy in the Quiwi TrialAdrián Mosquera Orgueira, Pau Montesinos, Manuel Pérez‐Encinas et al.|Blood|2023Cited by 1